A Phase II study of ERK inhibition by ulixertinib (BVD-523) in Metastatic Uveal Melanoma.

Elizabeth I Buchbinder Justine V Cohen Giuseppe Tarantino Christine G Lian David R Liu Rizwan Haq Frank Stephen Hodi Donald P Lawrence Anita Giobbie-Hurder Deborah Knoerzer Ryan J Sullivan

Published in: Cancer research communications (2024)

ERK inhibition with ulixertinib (BVD-523) did not demonstrate activity in patients with metastatic uveal melanoma. The toxicities observed were consistent with what would be expected with MAPK pathway inhibition.

Keyphrases

phase ii study
signaling pathway
pi k akt
cell proliferation
squamous cell carcinoma
small cell lung cancer
open label
oxidative stress
locally advanced
randomized controlled trial
clinical trial
radiation therapy
rectal cancer